<DOC>
	<DOCNO>NCT02389231</DOCNO>
	<brief_summary>The investigator demonstrate mean percentage circulate CD8+ regulatory T ( CD8 Tregs ) cell significantly high patient warm hemolytic anemia ( wAHAI ) remission control correlate hemoglobin level . In vitro , low dose interleukine-2 ( IL2 ) induce expansion CD8 Tregs . The objective demonstrate , 9 week treatment period ; low dos IL2 induce expansion CD8Tregs patient active wAHAI .</brief_summary>
	<brief_title>Evaluating Interest Interleukine-2 Patients With Active Warm Hemolytic Anemia Resistant Conventional Treatment</brief_title>
	<detailed_description>wAIHA B-cell-mediated autoimmune disease red blood cell targeted autoantibody , lead marked decrease lifespan . The investigator demonstrate two year ago multivariate retrospective study CD3+CD8+ HLA-DR+ T-cell population associate well outcome . The investigator observe proportion circulate CD3+CD8+CD25highFoxp3+ T cell significantly high patient wAIHA remission control correlate hemoglobin level . Extensive phenotyping functional analysis reveal cell bona fide Tregs act IL10-dependent manner . Finally , culture PBMC normal donor active wAIHAI patient low dose IL2 promote expansion functional CD3+CD8+CD25+Foxp3+ . Those observation constitute rationale propose low dose IL2 treat patient active wAIHA objective demonstrating treatment able induce expansion CD8Tregs , 9 week treatment period . Four course IL2 ( aldesleukin [ Proleukin , Novartis ] ) administer subcutaneously 5 day . The first course limit dose 1.5 million IU per day follow 9 day wash-out . The course 3 million IU per day initiate 16 day wash-out . Patients evaluate day 1 day 5 treatment course , first last administration interleukin-2 also evaluate 6 month .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Adults ( 18 year old ) wAHAI define presence hemolysis positive coombs test ( IgG +/C3 ) Absence infection hematologic disease wAHAI respond conventional steroid despite dose 10 mg No treatment rituximab minimum 6 month Signed informed consent form Less 18 year old Cold AHAI IL2 allergy Chemiotherapy immunosuppressive treatment Treatment rituximab le 6 month Neoplasia hematologic malignancy Aplastic anemia Neutropenia â‰¤ 1000 mm3 Infection Hepatitis B C wAHAI associate systemic lupus erythematosus depend ACR criterion Cardiac insufficiency Hypertension Pulmonary insufficiency Liver cirrhosis Thrombopenia 50000/mm3 Drug addiction , alcohol abuse Psychiatric disorder Absence sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>interleukine 2</keyword>
	<keyword>warm autoimmune hemolytic anemia</keyword>
	<keyword>CD8 regulatory T cell</keyword>
</DOC>